Arcturus Therapeutics Holdings Inc.
ARCT
$18.51
$1.035.89%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -43.24% | -22.70% | -26.22% | -7.68% | 373.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -43.24% | -22.70% | -26.22% | -7.68% | 373.99% |
| Cost of Revenue | -23.98% | -34.87% | 19.55% | -23.38% | 17.03% |
| Gross Profit | -45.09% | 64.58% | -264.51% | 142.77% | 571.01% |
| SG&A Expenses | -16.06% | -23.81% | -1.02% | -0.76% | -6.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -43.77% | -32.47% | 14.32% | -18.69% | 7.73% |
| Operating Income | 45.02% | 44.67% | -82.76% | 44.41% | 61.85% |
| Income Before Tax | 47.16% | 46.78% | -162.20% | 53.55% | 66.59% |
| Income Tax Expenses | 102.67% | -- | -101.53% | -124.30% | -126.00% |
| Earnings from Continuing Operations | 46.68% | 47.51% | -156.30% | 57.45% | 67.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 46.68% | 47.51% | -156.30% | 57.45% | 67.24% |
| EBIT | 45.02% | 44.67% | -82.76% | 44.41% | 61.85% |
| EBITDA | 46.40% | 45.69% | -86.60% | 46.85% | 63.00% |
| EPS Basic | 46.99% | 47.95% | -152.80% | 58.21% | 67.73% |
| Normalized Basic EPS | 47.48% | 47.24% | -158.64% | 54.40% | 67.09% |
| EPS Diluted | 46.99% | 47.95% | -151.18% | 58.21% | 67.73% |
| Normalized Diluted EPS | 47.48% | 47.24% | -158.64% | 54.40% | 67.09% |
| Average Basic Shares Outstanding | 0.60% | 0.85% | 1.40% | 1.84% | 1.52% |
| Average Diluted Shares Outstanding | 0.60% | 0.85% | 1.40% | 1.84% | 1.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |